Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 229 across all filing types
Latest filing 2024-06-04 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated June 4, 2024, from Concord Biotech Limited addressed to stock exchanges (NSE and BSE). It informs about the schedule of analyst and institutional investor meetings, specifically an Ambit Conference on June 7, 2024. The document states that discussions will be based on publicly available information and no unpublished price sensitive information will be shared. It is submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30(6), which relates to disclosure of events or information. The document does not contain any financial data, report, or detailed presentation but is an announcement of an upcoming investor interaction event. The length is short (2334 characters), and it is clearly an announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q4 and FY24 earnings conference call of Concord Biotech Limited held on May 28, 2024. It includes management commentary on financial results, operational performance, strategic initiatives, and a Q&A session format typical of earnings call transcripts. The document references the earnings call, financial results for the quarter and fiscal year, and includes management and moderator dialogue. It is not a brief announcement, a report publication notice, or a certification letter. Therefore, it fits the category of a Call Transcript (CT). The document length (15,000 characters) and content confirm it is the full transcript, not just a summary or announcement.
2024-06-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the earnings call recording for the fourth quarter and year ended March 31, 2024. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) and provides a link to the audio recording of the earnings call. The document does not contain the transcript or detailed financial data but is an announcement about the earnings call recording availability. The document length is short (2285 characters) and it primarily serves as a notification rather than the full earnings release or transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about the earnings call recording, not the earnings release itself or the call transcript.
2024-05-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation for the Fourth Quarter and Year ended March 31, 2024' and is addressed to stock exchanges as per SEBI regulations. It contains detailed financial highlights, operational updates, segment-wise revenue splits, consolidated profit & loss account, balance sheet, and cash flow statement data. The content is structured as a presentation with slides and charts, focusing on financial results, business performance, and outlook for investors. The document length is about 15,000 characters, indicating it is the full presentation rather than a brief announcement. There is no indication that this is a full annual report (10-K) or interim report (IR) with statutory financial statements, nor is it a regulatory filing or certification. The document matches the description of an Investor Presentation (IP) which is a detailed presentation for investors focusing on financials, strategy, and market position.
2024-05-27 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document is a press release dated May 24, 2024, from Concord Biotech Limited addressed to the National Stock Exchange of India and BSE Limited. It contains extracts of the standalone and consolidated audited financial results for the fourth quarter and year ended March 31, 2024. The document references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results filings. The text mentions that the full format of the quarterly financial results is available on stock exchange websites and the company's website. The document is about financial results for a quarter and a fiscal year end but is presented as a press release with extracts, not the full detailed report itself. The length is about 15,000 characters, which is substantial but the content is primarily an announcement of the financial results extracts rather than a full annual report or detailed interim report. Given the focus on quarterly and year-end financial results extracts and the nature of the document as a press release, the best classification is Earnings Release (ER). FY 2024
2024-05-24 English
Updates
Notice of Dividend Amount Classification · 90% confidence The document is a letter addressed to stock exchanges (NSE and BSE) correcting a previously announced dividend percentage related to the audited financial results for the fiscal year ended March 31, 2024. It clarifies a typographical error in the dividend percentage from 30% to 875%. The document is short (2084 characters) and serves as a correction notice rather than the actual financial report or dividend declaration itself. It is an announcement related to dividend information but does not provide the dividend amount or payment details formally. Given the nature of the correction specifically about dividend percentage and its communication to exchanges, the most appropriate classification is Notice of Dividend Amount (DIV), as it pertains to dividend information correction. Confidence is high due to clear dividend correction context and communication to exchanges.
2024-05-23 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.